FreeAgent c09d03a7866bebcdb0df19a92c04913a436ec46b false No description of principal activity 01 December 2022 30 November 2023 129977282022-12-012023-11-30 12997728uk-bus:Director12022-12-012023-11-30 12997728uk-bus:AuditExempt-NoAccountantsReport2022-12-012023-11-30 12997728uk-bus:Micro-entities2022-12-012023-11-30 12997728uk-bus:FullAccounts2022-12-012023-11-30 12997728uk-bus:PrivateLimitedCompanyLtd2022-12-012023-11-30 12997728uk-bus:RegisteredOfficeuk-countries:UnitedKingdom2022-12-012023-11-30 129977282022-12-01 129977282023-11-30 12997728uk-core:CurrentFinancialInstruments2023-11-30 12997728uk-core:Non-currentFinancialInstruments2023-11-30 129977282021-12-012022-11-30 129977282022-11-30 12997728uk-core:CurrentFinancialInstruments2022-11-30 12997728uk-core:Non-currentFinancialInstruments2022-11-30 iso4217:GBP xbrli:pure

Tomal Ltd

Unaudited financial statements for the year ended 30 November 2023


Company information

Tomal Ltd is a private company limited by shares, registered in England and Wales, registered number 12997728.

The company's registered office is: 15 Melville House Longmore Avenue, Barnet, EN5 1LH, United Kingdom.

Balance Sheet

as at 30 November 2023

2023 2022
£ £
Current assets 1,251.78 549.68
Creditors: amounts falling due within one year (20,418.29) (8,518.29)
Net current assets / (liabilities) (19,166.51) (7,968.61)
Total assets less current liabilities (19,166.51) (7,968.61)
Net assets (19,166.51) (7,968.61)
Capital and reserves (19,166.51) (7,968.61)

For the year ending 30 November 2023 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

These accounts have been prepared in accordance with the micro-entity provisions and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

Directors' responsibilities:

Approved by the board of directors and signed on behalf of the board,

Tomasz Kiska
31 August 2024

Notes to the accounts

  1. Average number of employees

    During the year the average number of employees was 4 (2022: 4).

  2. Capital Commitments Note

    At the end of the financial year, the company had no contracted capital commitments. The company has focused its resources on ongoing pharmaceutical consulting and technological development projects. Any significant future capital commitments will be detailed in subsequent financial statements.

  3. Contingent Liabilities Note

    The company does not have any contingent liabilities as of the end of the financial year. All liabilities recognized on the balance sheet represent actual obligations. Should any contingent liabilities arise in the future, they will be disclosed in accordance with applicable accounting standards.

  4. Director Advances Credits Note

    Director Advances and Credits: During the year, there were no advances or credits granted by the company to its directors. No balances were outstanding at the year-end under such arrangements.

  5. Director Guarantees Note

    Director Guarantees: The directors have not provided any personal guarantees on behalf of the company during the financial year. Any guarantees made by directors in the future will be disclosed appropriately.

  6. Financial Commitments Note

    At the balance sheet date, the company had no financial commitments under operating leases, finance leases, or similar arrangements. The company's financial obligations are limited to the liabilities recognized on the balance sheet, which primarily include creditors due within one year.